Publication Name	World Journal of Hepatology
Manuscript ID	16100
Country	Greece

Received	2014-12-26 08:48
Peer-Review Started	2014-12-30 09:31
To Make the First Decision	2015-01-20 13:41
Return for Revision	2015-01-23 09:28
Revised	2015-02-10 00:00
Second Decision	2015-02-27 09:40
Accepted by Journal Editor-in-Chief	2015-02-27 16:09
Accepted by Company Editor-in-Chief	2015-03-18 17:19
Articles in Press	2015-03-18 17:19
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-05-01 18:06
Publish the Manuscript Online	2015-05-19 17:28

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues
Manuscript Source	Invited Manuscript
All Author List	Irene Rapti and Stephanos Hadziyannis
Funding Agency and Grant Number
Corresponding Author	Stephanos Hadziyannis, Emeritus Professor of Medicine and Hepatology, Liver Unit and its Molecular Biology Laboratory, National and Kapodistrian University of Athens, Evgenidion Hospital of Athens, 4 Dirrachiou Str., 15669 Athens, Greece. hadziyannis@ath.forthnet.gr
Key Words	Chronic hepatitis B; Cirrhosis; Hepatocellular carcinoma; Hepatitis B virus; Treatment; Interferon; Lamivudine; Adefovir; Entecavir; Tenofovir; Virological remission; Nucleos(t)ide analogues
Core Tip	Hepatocellular carcinoma (HCC) represents a major health problem worldwide. It develops on the grounds of chronic liver disease, with chronic hepatitis B virus infection (CHB) being responsible for more than 50% of HCC worldwide. Currently, the vast majority of patients with CHB are being treated with nucleos(t)ide analogues, which have changed the natural history of the disease, reducing at a considerable extent its long-term consequences. However, although the risk of HCC has also been reduced, it has not been eliminated even after HBsAg loss or seroconversion. Therefore, constant surveillance, according to guidelines should never be omitted, unless new more potent treatment options are identified.
Publish Date	2015-05-19 17:28
Citation	Rapti I, Hadziyannis S. Risk for hepatocellular carcinoma in the course of chronic hepatitis B virus infection and the protective effect of therapy with nucleos(t)ide analogues. World J Hepatol 2015; 7(8): 1064-1073
URL	http://www.wjgnet.com/1948-5182/full/v7/i8/1064.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i8.1064

Full Article (PDF)	WJH-7-1064.pdf
Full Article (Word)	WJH-7-1064.doc
Manuscript File	16100-Review.docx
Answering Reviewers	16100-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	16100-Conflict-of-interest statement.pdf
Copyright License Agreement	16100-Copyright assignment.pdf
Peer-review Report	16100-Peer-review(s).pdf
Scientific Misconduct Check	16100-Scientific misconduct check.pdf
Scientific Editor Work List	16100-Scientific editor work list.pdf